# PTPN9

## Overview
PTPN9 is a gene that encodes the protein tyrosine phosphatase non-receptor type 9, a member of the protein tyrosine phosphatase (PTP) family. This family of enzymes is involved in the regulation of various cellular processes through the dephosphorylation of tyrosine residues on target proteins. PTPN9 is characterized by a catalytic domain typical of PTPs and a unique Sec14 homology domain, which is implicated in vesicle fusion and transport (Chou2020PTPN9mediated; Kim2022Structure–Activity). The protein plays a significant role in autophagy and erythroid cell development by modulating key signaling pathways and protein interactions. It is also involved in cancer biology, acting as a tumor suppressor in certain contexts, and has been linked to neurodegenerative diseases through its role in autophagy (Hong2016miR96; Bu2014Protein). The diverse functions of PTPN9 underscore its importance in maintaining cellular homeostasis and its potential as a therapeutic target in various diseases.

## Structure
PTPN9, a protein tyrosine phosphatase, features a catalytic domain typical of protein tyrosine phosphatases, characterized by conserved motifs such as the HCX5R motif within the P-loop and the WPD loop. These motifs are crucial for substrate coordination and catalytic dephosphorylation (Kim2022Structure–Activity; Gone2024Exploring). The protein also contains a unique phosphoinositide-binding Sec14 homology domain at the NH2 terminus, which is relevant to its function in vesicle fusion and transport (Chou2020PTPN9mediated).

PTPN9 is involved in the dephosphorylation of specific proteins, such as VTI1B, which is crucial for autophagosome formation. This activity highlights its role in cellular processes like autophagy (Chou2020PTPN9mediated). The protein's structure allows it to interact with other proteins through hydrophobic and π-π stacking interactions, as seen in its interaction with synthetic ginkgolic acid analogs (Kim2022Structure–Activity).

PTPN9 can undergo post-translational modifications, including phosphorylation, which may regulate its activity and interactions (Chou2020PTPN9mediated). The protein may exist in different isoforms due to alternative splicing, although specific details on these isoforms are not provided in the context.

## Function
PTPN9, a protein tyrosine phosphatase, plays a crucial role in regulating autophagy and erythroid cell development in healthy human cells. In the context of autophagy, PTPN9 is involved in the early stages of autophagosome formation by dephosphorylating the SNARE protein VTI1B. This dephosphorylation enhances the fusion of ATG16L1 precursors, which is essential for autophagosome biogenesis and autophagic flux. PTPN9's activity is critical for maintaining cellular homeostasis, particularly under nutrient starvation conditions, by promoting the assembly of SNARE complexes necessary for membrane fusion processes (Chou2020PTPN9mediated).

In erythroid cell development, PTPN9 regulates the maturation of erythroid cells by dephosphorylating STAT3. This action prevents the formation of an inhibitory complex involving phosphorylated STAT3, GATA1, and ZBP-89, which otherwise impedes erythroid differentiation. By modulating STAT3 phosphorylation, PTPN9 ensures proper erythroid gene expression and cell maturation, highlighting its role in erythropoiesis (Bu2014Protein).

PTPN9 is active in the cytoplasm, where it interacts with various proteins to modulate signal transduction pathways, impacting cellular processes such as growth, differentiation, and metabolism (Bu2014Protein).

## Clinical Significance
Alterations in the expression or function of the PTPN9 gene have been implicated in several diseases, particularly in cancer and neurodegenerative disorders. In breast cancer, PTPN9 acts as a tumor suppressor by dephosphorylating proteins such as EGFR, ErbB2, and STAT3, which are involved in cancer progression. The microRNA miR-96, which is upregulated in breast cancer, targets PTPN9, leading to its downregulation. This interaction promotes cancer cell proliferation, migration, and invasion, suggesting that miR-96 contributes to breast tumorigenesis by silencing PTPN9 (Hong2016miR96).

PTPN9 is also involved in autophagy, a process crucial for cellular homeostasis and implicated in neurodegenerative diseases. PTPN9 regulates autophagosome formation by dephosphorylating the SNARE protein VTI1B, which is essential for vesicle fusion. Alterations in PTPN9 expression or function can impair autophagic flux, potentially contributing to neurodegenerative conditions characterized by protein aggregation. In Drosophila models, overexpression of a PTPN9 homolog has shown neuroprotective effects, suggesting its potential as a therapeutic target for neurodegenerative diseases (Chou2020PTPN9mediated).

These findings highlight the clinical significance of PTPN9 in cancer and neurodegenerative diseases, indicating its potential as a therapeutic target.

## Interactions
PTPN9, a protein tyrosine phosphatase, engages in several critical interactions with other proteins, influencing various cellular processes. It interacts with SNARE proteins, including VTI1B, VAMP7, STX7, and STX8, which are essential for membrane fusion processes involved in autophagy. PTPN9 specifically dephosphorylates VTI1B at tyrosine residues Y112 and Y115, a modification crucial for the assembly of SNARE complexes and the regulation of autophagic flux (Chou2020PTPN9mediated).

In erythroid cell development, PTPN9 interacts with and dephosphorylates STAT3, a transcription factor. This interaction is vital for erythroid cell maturation, as it prevents the formation of an inhibitory complex involving phosphorylated STAT3, GATA1, and ZBP-89, which would otherwise hinder erythroid gene expression (Bu2014Protein).

PTPN9 also plays a role in cancer biology. In breast cancer, it is targeted by miR-96, which promotes cell proliferation and invasion by downregulating PTPN9. This interaction forms part of a feedback loop involving miR-96 and STAT3, where PTPN9 dephosphorylates STAT3, affecting its activity (Hong2016miR96). In colorectal cancer, PTPN9 negatively regulates the activation of STAT3, influencing cell apoptosis and acting as a tumor suppressor (PTPN9; Wang2019&lt; p&gt).


## References


[1. (Kim2022Structure–Activity) Jinsoo Kim, Jinyoung Son, Dohee Ahn, Gibeom Nam, Xiaodi Zhao, Hyuna Park, Woojoo Jeong, and Sang J. Chung. Structure–activity relationship of synthetic ginkgolic acid analogs for treating type 2 diabetes by ptpn9 inhibition. International Journal of Molecular Sciences, 23(7):3927, April 2022. URL: http://dx.doi.org/10.3390/ijms23073927, doi:10.3390/ijms23073927. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23073927)

[2. (Hong2016miR96) Yeting Hong, Hongwei Liang, Uzair-ur-Rehman, Yanbo Wang, Weijie Zhang, Yong Zhou, Song’an Chen, Mengchao Yu, Sufang Cui, Minghui Liu, Nan Wang, Chao Ye, Chihao Zhao, Yanqing Liu, Qian Fan, Chen-Yu Zhang, Jianfeng Sang, Ke Zen, and Xi Chen. Mir-96 promotes cell proliferation, migration and invasion by targeting ptpn9 in breast cancer. Scientific Reports, November 2016. URL: http://dx.doi.org/10.1038/srep37421, doi:10.1038/srep37421. This article has 82 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep37421)

[3. (Bu2014Protein) Ye Bu, Fuqin Su, Xu Wang, Hai Gao, Lei Lei, Nannan Chang, Qing Wu, Keping Hu, Xiaojun Zhu, Zhijie Chang, Kun Meng, and Jing-Wei Xiong. Protein tyrosine phosphatase ptpn9 regulates erythroid cell development through stat3 dephosphorylation in zebrafish. Journal of Cell Science, January 2014. URL: http://dx.doi.org/10.1242/jcs.145367, doi:10.1242/jcs.145367. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.145367)

[4. (Chou2020PTPN9mediated) He-Yen Chou, Yi-Tang Lee, Yuchieh Jay Lin, Jung-Kun Wen, Wen-Hsin Peng, Pei-Lien Hsieh, Shu-Yu Lin, Chin-Chun Hung, and Guang-Chao Chen. Ptpn9-mediated dephosphorylation of vti1b promotes atg16l1 precursor fusion and autophagosome formation. Autophagy, 17(10):2750–2765, October 2020. URL: http://dx.doi.org/10.1080/15548627.2020.1838117, doi:10.1080/15548627.2020.1838117. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1080/15548627.2020.1838117)

[5. (Gone2024Exploring) Geetanjali B. Gone, Geonhui Go, Gibeom Nam, Woojoo Jeong, Hyemin Kim, Soah Lee, and Sang J. Chung. Exploring the anti-diabetic potential of quercetagitrin through dual inhibition of ptpn6 and ptpn9. Nutrients, 16(5):647, February 2024. URL: http://dx.doi.org/10.3390/nu16050647, doi:10.3390/nu16050647. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/nu16050647)